Breaking News
Sort by:
Top Post
Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease
An experimental drug already tested as a potential treatment for cancer, lung, and Alzheimer’s disease […]
Cambrian Bio launches Amplifier Therapeutics to Develop Clinical-Stage AMPK Activator
Cambrian Bio, a clinical-stage biotechnology company focused on treating and preventing chronic diseases of aging, […]
Vesigen Therapeutics Awarded Grant from Friedreich’s Ataxia Research Alliance (FARA) to Develop a Targeted Genome Editing Therapeutic Strategy
Vesigen Therapeutics, a biotechnology company developing targeted therapies by engineering a distinct class of human […]
BlueRock Therapeutics to use Rune Labs' Clinical Trial Platform to Better Characterize Parkinson's Disease State in Cell Therapy Trials
Rune Labs, a precision neurology software and data platform company, today announced a partnership with […]
Cantargia Treats First Triple-Negative Breast Cancer Patient in Randomized Phase II Part of TRIFOUR Trial
Cantargia today reported that, following positive results in the lead-in phase of the clinical phase […]
Porton Advanced and Bennu Biotherapeutics Announced a Strategic Partnership to Accelerate Cell Therapy Development for Solid Tumors
Porton Advanced Solutions and Bennu Biotherapeutics have announced a strategic partnership to advance cell and […]
BIOCORP Signs With HRA Pharma for the Development of a Medical Device Innovation
BIOCORP, a French company specialized in the design, development, and manufacturing of innovative medical devices, […]
China National Medical Products Administration Accepts Regulatory Submission for Nucala (mepolizumab) in Severe Eosinophilic Asthma
GSK today announced that the China National Medical Products Administration has accepted for review a […]
Telix's ZIRCON Phase III Kidney Cancer Imaging Study Presented in "Game Changing" Session at EAU
Telix Pharmaceuticals today announces additional positive results from its completed pivotal Phase III ZIRCON study […]
U.S. Veterans' Health Administration (VHA) Provides Coverage of LEQEMBI™ (lecanemab-irmb) for Veterans Living with Early Stages of Alzheimer's Disease
BioArctic AB’s partner Eisai announced today that the U.S. Veterans Health Administration (VHA) is providing […]
Calliditas Announces Primary Endpoint Successfully Met in Phase 3 NefIgArd Trial Evaluating Nefecon® in IgA Nephropathy
Calliditas Therapeutics has announced positive topline results from the global, randomized, double-blind, placebo-controlled Phase 3 […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more